BRAINSTORM CELL THERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
BCLI$0.97+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · | ||||||
| · · December 31, | ||||||
| · 2023 · 2022 | ||||||
| · · U.S. $ in thousands | ||||||
| Cash flows from operating activities: | | | ||||
| | | | | | | |
| Net loss | | $(17,192) | | $(24,277) | ||
| | | | | | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | ||
| Depreciation | | 265 | | 285 | ||
| Stock-based compensation related to options granted to employees and directors | | 1,490 | | 1,682 | ||
| Change in operating lease liability, net | | 155 | | (594) | ||
| Decrease (increase) in prepaid expenses and other accounts receivable | | | (475) | | | 1,067 |
| Increase (decrease) in trade payables | | (1,270) | | 2,524 | ||
| Gain on change in fair value of warrants (Note 9) (*) | | (4,525) | | — | ||
| Increase (decrease) in employees related liability and accrued expenses | | 1,094 | | | (7) | |
| Total net cash used in operating activities | | $(20,458) | | $(19,320) | ||
(*) Presented after neutralizing costs of issuance.
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year ended | ||||||
| · · December 31, | ||||||
| · 2023 · 2022 | ||||||
| · · U.S. $ in thousands | ||||||
| Cash flows from investing activities: · · · · | ||||||
| | | | | | | |
| Purchase of property and equipment | | (18) | | (29) | ||
| Changes in short-term deposit | | 2,211 | | 1,027 | ||
| Total net cash provided by investing activities | $2,193 | $998 | ||||
| | | | | | | |
| Cash flows from financing activities: | | | | | | |
| Proceeds from issuance of shares in at-the-market (ATM) offering (Note 10) | | 11,881 | | 238 | ||
| Proceeds from Issuance of shares for private placement (Note 10) (*) | | 7,097 | | — | ||
| Total net cash provided by financing activities | | $18,978 | | $238 | ||
| Increase (decrease) in cash and cash equivalents | | | 713 | | | (18,084) |
| | | | | | ||
| Cash, cash equivalents and restricted cash at the beginning of the period | | $772 | | $18,856 | ||
| | | | | | | |
| Cash, cash equivalents and restricted cash at end of the period | | $1,485 | | $772 | ||
(*) Presented after neutralizing costs of issuance.
| | | | | |
|---|---|---|---|---|
| · · Year ended | ||||
| · · December 31, | ||||
| · 2023 · 2022 | ||||
| Non-Cash Activities: · · USD in thousands | ||||
| Right of use (“ROU”) asset recognized with corresponding lease liability, resulted from new lease agreement (Note 5) | | — | | 1,576 |
| ROU asset decreased, resulted from lease modification (Note 5) | | 1,695 | | — |
| Lease liability decreased, resulted from lease modification (Note 5) | | 1,395 | | |
| Finance expenses resulted from lease modification (Note 5) | | 300 | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.